The gas-sensing capsule assesses the functional health of a patient’s entire gastrointestinal system and aims to provide: better diagnosis, more targeted and personalized treatment, earlier relief of symptoms and improved healthcare outcomes.
The capsule can electronically report important data by continuously detecting gases and wirelessly transmitting the data to provide insights into the location of the capsule, microbiome function and gastrointestinal health.
The ingestible capsule offers a potential diagnostic tool for many disorders of the gut from motility disorders, IBS and IBD to liver disease.
The Atmo Gas Capsule is currently an investigational device exclusively for use in clinical investigations, and is not available for sale.
Gut disorders are one of the most common ailments in the world affecting tens of millions of people.
These disorders include motility abnormalities, SIBO, IBS and IBD. Gases are important biomarkers of disease, dysfunction and dysbiosis.
The vitamin-sized electronic “Lab-in-a-Pill” measures gaseous biomarkers at the source of production as it passes through the gastrointestinal system. This data is continuously transmitted to a pocket-sized receiver, and sent to the cloud for aggregation, analysis, and diagnosis.
The gas sensors are sealed within a special membrane that allows gas in but keeps out stomach acid and digestive juices.
The capsule aims to determine transit times derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of multi-gas, capsule tumble, and antenna reflectance.
November 16, 2023. An editorial published in the journal Alimentary Pharmacology and Therapeutics describes Atmo Biosciences’ gas-sensing capsule as disruptive technology that has enabled unlocking ...
November 13, 2023. Atmo Biosciences is pleased to announce that the Japan Patent Office has granted a patent related to key intellectual property for Atmo’s ingestible gas-sensing capsule....
October 26, 2023. Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificia...
October 19, 2023. The Atmo Gas Capsule could be used to help understand and monitor duodeno-gastric reflux and provide insight into its connection to delayed gastric emptying, according to an investig...
October 3, 2023. Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in p...
September 25, 2023. Breakthrough Victoria today announced it has invested in Atmo Biosciences to support the commercialization of the company’s world-first ingestible gas-sensing capsule that can he...
Kalantar-Zadeh, K., Berean, K.J., Burgell, R.E. et al. Intestinal gases: influence on gut disorders and the role of dietary manipulations. Nat Rev Gastroenterol Hepatol 16, 733–747 (2019). https://doi.org/10.1038/s41575-019-0193-z
David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology.
Houston Methodist Hospital
Chief of Gastroenterology and Hepatology.
University of Michigan
Distinguished University Chair in Gastroenterology & Professor of Medicine. Director, Neurogastroenterology/Motility and Digestive Health Clinical Research Center.
Professor of Medicine, Vice-Chief of the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine.
David Geffen School of Medicine at UCLA
Director of Research for Digestive Disease & Surgery Institute.
Director of Center for Neurointestinal Health at Massachusetts General Hospital and Associate Professor at Harvard Medical School.